Press release
Cartherics grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China
Melbourne, Australia, 28 April 2023 - Cartherics Pty Ltd ("Cartherics"), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has granted Shunxi Holding Group Co Ltd ("Shunxi") a licence to develop, manufacture and commercialise Cartherics' autologous CAR-T cell product, CTH-004, for the treatment of multiple solid tumours including ovarian cancer in Greater China.CTH-004 has shown promising results in animal models of ovarian cancer and will be evaluated in a clinical trial under a research and development collaboration with the Peter MacCallum Cancer Centre, announced earlier this year.
Globally, approximately 314,000 new ovarian cancer cases and 207,000 deaths occurred in 2020. In China, a recent study revealed that the burden of ovarian cancer has shown an obvious upward trend in the past 30 years, and the increase rate accelerated significantly in recent 5 years. In the next decade, ovarian cancer burden in China will continue to rise at a higher rate than the global level.
There is a significant clinical need for new treatment options for patients with ovarian cancer. Cartherics CEO, Alan Trounson AO, commented: "We are pleased to see this potentially effective therapy for ovarian cancer being adopted and trialled in China where there are many women suffering the heavy burden of ovarian cancer. We hope that women worldwide will benefit from this therapy."
Chairman of Shunxi Holding Group, Mr Xia Jie, believes that this CAR-T cell product co-developed by Cartherics and Shunxi will explore a new path for treating recurrent ovarian cancer since ovarian cancer has high rates of recurrence.
This agreement provides Shunxi Holding Group a licence to develop, manufacture and commercialise CTH-004 for Greater China (Including Mainland China, Hong Kong, Macao and Taiwan), as well as an option to negotiate rights to other CAR-T products that incorporate the licenced IP. The structure of the agreement involves a licence fee, milestone payments and royalties.
Dr. Shu Runzhe, Cartherics' deputy CSO, will join Shunxi to lead the pre-clinical and clinical development of CTH-004 in China. Cartherics and Shunxi will share CTH-004 pre-clinical and clinical data in future. Cartherics retains all development and commercialisation rights for CTH-004 outside Greater China.
12 Ferntree Place
Notting Hill, VIC
Australia, 3168
Media Contact
Christine Filippis
Phone: +61 419 119 866
Email: christine@teraze.com.au
About Cartherics
Cartherics is a privately held biotechnology company based in Melbourne, Australia that is rearming the body's immune system to fight cancer. It is developing cell-based immunotherapies for the treatment of cancer, with a portfolio of CAR-T and CAR-NK cell products. The Company's allogeneic ("off-the-shelf") cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system. The iPSCs are genetically engineered to provide enhanced function for the derived NK and other immune cells.
The Company is also developing autologous CAR-T cell therapies. These use the patient's own immune system T cells, which are modified to be effective against the patient's cancer cells. CTH-004 is created by genetically modifying patient T cells to insert a chimeric antigen receptor (CAR) to target a marker (TAG-72) on ovarian cancer cells and delete genes that are involved in suppression of T cell function. https://cartherics.com/
About Shunxi Holding Group
Shunxi Holding Group is a group company headquartered in Shanghai, China, specializing in medical services and innovative drug development, committed to improving the quality of life for every Chinese person. The Regenerative Medicine sector under the Group is the operator of "Yunnan Stem Cell Bank" and "Yunnan Ethnic Minority Biological Sample Bank". It has built the largest stem cell bank in southwest China, and leads the industry in the field of mesenchymal stem cell clinical translation research in China. The Medical Service sector invested by the group includes health examinations and third-party medical testing, providing high-quality and efficient medical services to tens of millions of Chinese people every year.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cartherics grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China here
News-ID: 3033870 • Views: …
More Releases from Cartherics

CARTHERICS TO PRESENT AT THE 2025 BIO INTERNATIONAL CONVENTION
• Cartherics' Chief Operating Officer, Dr. Ian Nisbet, will be presenting at BIO on Monday 16th June, 2025 at 1.30pm (US EDT).
Melbourne, Australia, 28 May 2025 - Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, announced today that Dr. Ian Nisbet, COO, will present at the upcoming 2025 BIO International Convention June 16-19 2025, in Boston Massachusetts.…

CARTHERICS RAISES OVER $15 MILLION IN OVERSUBSCRIBED PRIVATE FINANCING ROUND TO …
• Financing round was significantly oversubscribed by existing investors and new private investors.
• Funding will enable the Company to progress clinical trials of its lead CAR-NK cell therapy product, CTH-401, in ovarian cancer and expand its pipeline to additional disease indications.
Melbourne, Australia, 1 October 2024 - Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the treatment of cancer and other diseases, is pleased to announce…

CARTHERICS ENTERS AGREEMENTS WITH UNIQUEST, THE UNIVERSITY OF QUEENSLAND AND THE …
• Cartherics, UniQuest and The University of Sydney enter Technology Licence Agreement for Cartherics' iPSC cell line.
• Cartherics, The University of Queensland and The University of Sydney enter Material Transfer Agreement to support development of iPSC-derived cardiomyocytes for the treatment of cardiovascular disease.
Melbourne, Australia, 25 July 2024 - Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that…

CARTHERICS GRANTED EUROPEAN PATENT FOR MULTIPLE DEVELOPMENT CANDIDATES
Melbourne, Australia, 23 May 2024 - Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its second European Patent from the family represented by the international patent filing WO2017088012.
The European Patent No. 3708587 B1, titled 'Genetically Modified Cells and Uses Thereof,' secures a proprietary position for multiple development candidates in…
More Releases for Shu
$1 Billion SEC Scandal Unfolds as Whistleblower Shaman Shu Demands Accountabilit …
Washington, D.C. - June 2025: A wave of public scrutiny is sweeping across the U.S. Securities and Exchange Commission following a shocking disclosure by federal whistleblower Shaman Shu (Robert Shumake). In what legal analysts now call the largest expert fraud in modern SEC history, Shu has exposed 21 federal cases tainted by false credentials used in official testimony.
The controversy centers around Pesach Glaser, an individual repeatedly presented by the SEC…
Shaman Shu Exposes $1 Billion SEC Scandal as Protected Federal Whistleblower
June 2025 - New York, NY: Shaman Shu, also known as Robert Shumake and legally known as Bobby Japhia, has come forward as a federally certified whistleblower in what is shaping up to be the largest credential fraud scandal in SEC history. At stake: over $1 billion in contaminated case outcomes and the reputations of dozens of SEC enforcement rulings.
At the center of the disclosure is Pesach Glaser, who falsely…
Shaman Shu Exposes $1 Billion SEC Scandal as Protected Federal Whistleblower
June 2025 - New York, NY: Shaman Shu, born Robert Shumake and legally known as Bobby Japhia, has come forward as a federally protected whistleblower exposing what may be the largest credential fraud in SEC history-a case that could unravel over $1 billion in court decisions and settlements.
Shu's disclosure identifies false testimony submitted by an unqualified expert, Pesach Glaser, across 21 SEC enforcement actions, potentially affecting more than 2,000 investors…
Ajarn Shaman Shu and Soul Tribes Ministries Launch The House of Shu TV - The Wor …
With a focus on mental health, spiritual wellness, and holistic transformation, The House of Shu TV brings ancient healing practices to the modern world, available to everyone at no cost.
The House of Shu, led by Ajarn Shaman Shu, is thrilled to announce the launch of The House of Shu TV, the world's first free shamanic healing TV network. Available on YouTube, Roku, Amazon Fire TV, Apple TV, and other OTT…
Eyelash Curlers Market 2019 Future Demand - TOUCHBeauty, KAI, Shu Uemura, Shisei …
Published via Market Research Place, a new market research study Global Eyelash Curlers Market 2019 presents an inclusive study on market segmentation, future scope, development strategies, competitive breakdown, and regional forecast for 2019 to 2025 time-frame. The report focuses on the existing top players and upcoming competitors. The report puts a strong focus over some of the significant sections of the Eyelash Curlers market, important factors boosting or obstructing the…
Global Handmade Eyelash Market 2017 - 2022 : Ardell, ESQIDO, Elf, Kiss, Revlon, …
Handmade Eyelash Market 2017 Industry research report provides important information to identify and analyze the market need, market size and competition. This market research report used in maintaining competitiveness over competitors.
Scope of the Report:
This report focuses on the Handmade Eyelash in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Request for Sample…